onMRIAI-powered Objective MRI Analysis

Transforming subjective MRI interpretation into standardized, quantifiable measurements for superior diagnostic accuracy in musculoskeletal imaging

See onMRI in Action

Research Team

Paul Lee

Lead Researcher

Tanvi Verma

Co-Researcher

MSK Doctors, Sleaford, United Kingdom

Background

Conventional musculoskeletal MRI interpretation relies on subjective visual grading, introducing inter-reader variability that undermines clinical consistency and limits the early detection of joint degeneration or therapeutic response. The onMRI platform addresses this gap by transforming MRI into a standardised, quantitative tool using AI-powered segmentation and biomarker extraction.

Methods

Study Cohort

  • 150 musculoskeletal MRI scans analyzed
  • Meniscal injury cases included
  • Post-operative ACL reconstruction patients
  • Regenerative cartilage therapy patients

AI Technology

  • Deep learning segmentation algorithms
  • 3D anatomical reconstructions
  • Objective biomarker measurements
  • Uniform anatomical definitions

Results

100%
Successful Segmentation Rate
3D
High-Fidelity Models
150
Scans Analyzed
Femoral Cartilage Analysis

Femoral Cartilage

Tibial Cartilage Analysis

Tibial Cartilage

Medial Meniscus Analysis

Medial Meniscus

Key Achievements

Quantitative Biomarkers

  • • Cartilage thickness measurements
  • • Volume calculations
  • • Contact area analysis
  • • Joint space width assessment

Clinical Impact

  • • Superior sensitivity to sub-radiological changes
  • • Early regenerative response detection
  • • Reproducible cross-patient comparisons
  • • Enhanced diagnostic accuracy

Conclusion

onMRI enables the quantification of joint structures in a consistent, reproducible manner, offering a powerful alternative to subjective MRI interpretation. It holds significant promise for improving diagnostic accuracy, monitoring disease progression, and evaluating the efficacy of regenerative and surgical interventions in musculoskeletal care.

Further large-scale validation is underway to integrate these imaging biomarkers with clinical outcomes and motion data.